Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)

TitleUse of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator)
Publication TypeJournal Article
Year of Publication2008
AuthorsBuckingham, B., Xing D., Weinzimer S., Fiallo-Scharer R., Kollman C., Mauras N., Tsalikian E., Tamborlane W., Wysocki T., Ruedy K., & Beck R.
Corporate AuthorsDiabetes Research in Children Network(DirecNet) Study Group
JournalPediatric diabetes
Volume9
Issue2
Pagination142-7
Date Published2008 Apr
ISSN1399-5448
KeywordsAdolescent; Algorithms; Blood Glucose; Child; Computer Systems; Diabetes Mellitus; Feasibility Studies; Humans; Insulin Infusion Systems; Monitoring, Ambulatory; Monitoring, Physiologic; Patient Satisfaction
Abstract

BACKGROUND: There are no published guidelines for use of real-time continuous glucose monitoring data by a patient; we therefore developed the DirecNet Applied Treatment Algorithm (DATA). The DATA provides algorithms for making diabetes management decisions using glucose values: (i) in real time which include the direction and rate of change of glucose levels, and (ii) retrospectively based on downloaded sensor data.
OBJECTIVE: To evaluate the use and effectiveness of the DATA in children with diabetes using a real-time continuous glucose sensor (the FreeStyle Navigator).
SUBJECTS: Thirty children and adolescents (mean +/- standard deviation age = 11.2 +/- 4.1 yr) receiving insulin pump therapy.
METHODS: Subjects were instructed on use of the DATA and were asked to download their Navigator weekly to review glucose patterns. An Algorithm Satisfaction Questionnaire was completed at 3, 7, and 13 wk.
RESULTS: At 13 wk, all of the subjects and all but one parent thought that the DATA gave good, clear directions for insulin dosing, and thought the guidelines improved their postprandial glucose levels. In responding to alarms, 86% of patients used the DATA at least 50% of the time at 3 wk, and 59% reported doing so at 13 wk. Similar results were seen in using the DATA to adjust premeal bolus doses of insulin.
CONCLUSIONS: These results show the feasibility of implementing the DATA when real-time continuous glucose monitoring is initiated and support its use in future clinical trials of real-time continuous glucose monitoring.






DOI10.1111/j.1399-5448.2007.00301.x
Alternate JournalPediatr Diabetes
Refereed DesignationRefereed